Australia markets closed

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
10.49+0.09 (+0.87%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 6.22B
Enterprise value 5.50B
Trailing P/E 21.35
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.03
Price/book (mrq)2.94
Enterprise value/revenue 6.41
Enterprise value/EBITDA 17.36

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-35.76%
S&P500 52-week change 322.36%
52-week high 317.47
52-week low 38.06
50-day moving average 310.46
200-day moving average 312.89

Share statistics

Avg vol (3-month) 35.63M
Avg vol (10-day) 35.14M
Shares outstanding 5593.07M
Implied shares outstanding 6593.07M
Float 8265.22M
% held by insiders 159.97%
% held by institutions 11.91%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.11
Forward annual dividend yield 41.07%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 40.38
Payout ratio 422.79%
Dividend date 3N/A
Ex-dividend date 412 July 2023
Last split factor 21.4:1
Last split date 312 July 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 31.89%
Operating margin (ttm)43.95%

Management effectiveness

Return on assets (ttm)5.93%
Return on equity (ttm)12.71%

Income statement

Revenue (ttm)855.13M
Revenue per share (ttm)1.44
Quarterly revenue growth (yoy)14.60%
Gross profit (ttm)N/A
EBITDA 324.11M
Net income avi to common (ttm)272.71M
Diluted EPS (ttm)0.49
Quarterly earnings growth (yoy)20.10%

Balance sheet

Total cash (mrq)1.11B
Total cash per share (mrq)1.88
Total debt (mrq)303.3M
Total debt/equity (mrq)13.40%
Current ratio (mrq)2.38
Book value per share (mrq)3.82

Cash flow statement

Operating cash flow (ttm)203.88M
Levered free cash flow (ttm)-37.94M